MyoPro expected to be reimbursed by CMS in a lump-sum payment rather than as a rental should the proposal be finalized following a 60-day public comment period
BOSTON (July 3, 2023)– Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces that its request to the Centers for Medicare and Medicaid Services (“CMS”) to classify the Company’s MyoPro as a brace has been published for public comment. Read more.